

December 10, 2021

IWAKI SEIYAKU CO., LTD.

**Announcement on Transfer of Manufacturing and Marketing Approval for
Topical Antifungal Agent “Nizoral® Lotion 2%”**

IWAKI SEIYAKU CO., LTD. (IWAKI SEIYAKU) and Janssen Pharmaceutical K.K. (Janssen) announce that both companies have agreed to the transfer of manufacturing and marketing approval for Nizoral® Lotion 2%. IWAKI SEIYAKU will start manufacturing, distributing, and marketing this product in Japan from April 1, 2022.

Nizoral® Lotion 2% is a lotion containing Ketoconazole, which has high antifungal action. In Japan, this product was approved in July 2003 for the indications of ringworm, cutaneous candidiasis, tinea versicolor, and seborrheic dermatitis.

IWAKI SEIYAKU is a pharmaceutical company focused on the manufacturing and distribution of ethical and OTC drugs. The company is especially active in the generic market of products for dermatological use. This transfer is the first opportunity for IWAKI SEIYAKU to handle this long-listed drug. IWAKI SEIYAKU will continue to expand its range of brands and product portfolio in the future, and will ensure the stable supply of this product.

Contact:

IWAKI SEIYAKU CO., LTD.

Administration Department

TEL: +81-3-3668-1570

E-mail: IS2501@iwakiseiyaku.co.jp